Tenecteplase in Acute Stroke: What About the Children?

Lisa R. Sun, Jenny L. Wilson, Michaela Waak, Amy Kiskaddon, Neil A. Goldenberg, Lori C. Jordan, Megan Barry

Research output: Contribution to journalReview articlepeer-review

Abstract

Tenecteplase is replacing alteplase as the fibrinolytic agent of choice for the acute management of ischemic stroke in many adult stroke centers due to practical and pharmacokinetic advantages in the setting of similar outcomes. Although thrombolytic use is increasing for acute childhood stroke, there is very limited experience with tenecteplase in children for any indication, and importantly, there are no data on safety, dosing, or efficacy of tenecteplase for childhood stroke. Changes in fibrinolytic capacity over childhood, pediatric pharmacological considerations such as age-specific differences in drug clearance and volume of distribution, and practical aspects of drug delivery such as availability in children's hospitals may impact decisions about transitioning from alteplase to tenecteplase for acute pediatric stroke treatment. Pediatric and adult neurologists should prepare institution-specific guidelines and organize prospective data collection.

Original languageEnglish (US)
Pages (from-to)1950-1953
Number of pages4
JournalStroke
Volume54
Issue number7
DOIs
StatePublished - Jul 1 2023

Keywords

  • alteplase
  • child
  • fibrinolytic agent
  • ischemic stroke
  • tenecteplase

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Fingerprint

Dive into the research topics of 'Tenecteplase in Acute Stroke: What About the Children?'. Together they form a unique fingerprint.

Cite this